Urologic Neoplasms Clinical Trial
Official title:
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Status | Completed |
Enrollment | 183 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age = 18 years at the time of consent 2. Histologically documented metastatic or locally inoperable advanced transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis) (T4b, N2, N3 or M1 disease) NOTE: Certain mixed histologies that are predominately (= 50%) TCC are eligible: squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated histology requires immunohistochemistry (IHC) consistent with a TCC origin. Mixed small-cell histologies are excluded 3. Measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria 4. No prior systemic chemotherapy with the following exceptions: - Prior use of radiosensitizing single agent therapy is allowed - Prior neoadjuvant and adjuvant chemotherapy may be allowed 5. Minimum of 21 days since prior major surgery or radiation therapy 6. Karnofsky performance status = 70% 7. Required laboratory values at baseline: - absolute neutrophil count (ANC) = 1.5 x 10^9 cells/L - platelet count = 125 x 10^9/L - calculated creatinine clearance = 60 mL/minute - bilirubin = 1.5 x upper limit of normal (ULN; = 2.5 x ULN if secondary to Gilbert's disease) - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN 8. If of child-bearing potential, willing to use contraceptives 9. Willing to give written informed consent Exclusion Criteria: 1. A candidate for potential curative surgery or radiotherapy 2. Intravesical therapy within the last 3 months 3. Documented brain metastasis or carcinomatous meningitis, treated or untreated. NOTE: Brain imaging is not required unless the patient has symptoms or physical signs of central nervous system (CNS) disease. 4. Peripheral neuropathy = Grade 2 5. Known serious hypersensitivity to gemcitabine, cisplatin or carboplatin 6. Current serious, uncontrolled medical condition such as congestive heart failure, angina, hypertension, arrhythmia, diabetes mellitus, infection, etc. or any condition such as a psychiatric illness which in the opinion of the investigator would make the patient unacceptable for the protocol 7. Cerebrovascular accident, myocardial infarction or pulmonary embolus within 6 months of randomization 8. Active second malignancy (except non-melanomatous skin cancer): active secondary malignancy is defined as a current need for cancer therapy or a high possibility (> 30%) of recurrence during the study 9. Pregnant or nursing (must have a negative serum or urine pregnancy test within 72 hours prior to randomization) 10. Participating in a concurrent clinical trial of an experimental drug, vaccine or device. Participation in an observational study is allowed |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Tom Baker Cancer Center | Calgary | Alberta |
Canada | Cross Cancer Center | Edmonton | Alberta |
Canada | Juravinski Cancer Centre | Hamilton | Ontario |
Canada | CHUM-Hospital Notre Dame | Montreal | Quebec |
Canada | R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health | Oshawa | Ontario |
Canada | Princess Margaret Hospital | Toronto | Ontario |
Canada | British Columbia Cancer Agency | Vancouver | British Columbia |
France | Centre Paul Papin | Angers Cedex 9 | Pays De La Loire |
France | Centre Hospitalier Régional et Universitaire - Hôpital | Bretonneau Tours | Centre |
France | Institut Paoli Calmettes | Marseille Cedex 9 | Provence Alpes Cote D'Azur |
France | Centre Antoine Lacassagne | Nice | Provence Alpes Cote d'Azur |
France | Institute Jean Godinot | Reims | Champagne-Ardenne |
France | Centre Hospitalier Universitaire de Rouen | Rouen | Haute-Normandie |
France | Medicale Centre René Gauducheau | St. Herblain Cedex | Pays de la Loire |
France | Centre Hospitalier Universitaire, Institut Gustave Roussy | Villejuif Cedex | Ile-de-france |
Germany | Universitätsklinikum Dresden | Dresden | Sachsen |
Germany | Johann-Wolfgang-Goethe-Universität Frankfurt | Frankfurt | Hessen |
Germany | Medizinische Hochschule Hannover | Hannover | Niedeersachen |
Germany | Universitätsklinikum Heidelberg | Heidelberg | Baden-Wuerttemberg |
Germany | Universitätsklinikum des Saarlandes | Homburg | Saarland |
Germany | Universitätsklinikum Jena | Jena | Thuringen |
Germany | Universitätsklinikum Magdeburg A.ö.R. | Magdeburg | Sachsen-Anhalt |
Germany | Universitätsklinikum Mainz | Mainz | |
Germany | Klinikum Rechts der Isar der Technischen Universität | München | Bayern |
Italy | Azienda Ospedaliero-Universitaria Policlinico di Modena | Modena | |
Italy | Fondazione IRCCS Policlinico San Matteo Pavia | Pavia | |
Italy | Unità Operativa di Oncologia Medica | Roma | |
Poland | Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy | Bydgoszcz | Kujawsko-Pomorskie |
Poland | Uniwersyteckie Centrum Kliniczne | Gdansk | Pomorskie |
Poland | Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie | Olsztyn | Warminski-Mazurskie |
Poland | NZOZ Europejskie Centrum Zdrowia Otwock | Otwock | Mazowieckie |
Poland | Centrum Onkologii Instytut im. M. Sklodowskiej-Curie | Warszawa | Mazowieckie |
Poland | Akademicki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu | Wroclaw | Dolnoslaskie |
Spain | Hospital Clinic I Provincial de Barcelona | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Vall d´Hebrón | Barcelona | |
Spain | Hospital General Universitario Gregorio Marañon | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Institut Català D'Oncologia, Hospital Duran i Reynals | Madrid | |
Spain | Instituto Valenciano de Oncología-Fundación (IVO-FINCIVO) | Valencia | |
United States | Montefiore Medical Center, Albert Einstein College of Medicine | Bronx | New York |
United States | Texas Oncology, P.A. | Dallas | Texas |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope National Medical Center | Duarte | California |
United States | Monter Cancer Center | Lake Success | New York |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | University of California Los Angeles | Los Angeles | California |
United States | USC Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Yale University | New Haven | Connecticut |
United States | Columbia University Medical Center | New York | New York |
United States | Urology Cancer Center and GU Research Network | Omaha | Nebraska |
United States | Radiological Associates of Sacramento | Sacramento | California |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
United States | Siteman Cancer Center, Washington University School of Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
OncoGenex Technologies | PRA Health Sciences |
United States, Canada, France, Germany, Italy, Poland, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival (OS) | OS is defined as the time from randomization to death from any cause; OS was censored on date of last contact for participants still alive at time of analysis. | Baseline to date of death by any cause (up to approximately 12 months) | No |
Secondary | Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, and Grade 3 or Higher AEs | Treatment-emergent AEs are defined as and AE that occurred after the first dose of study drug up to 30 days after the last dose of study drug. AEs were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment-emergent AEs could have occurred during loading dose period, chemotherapy period, maintenance period, and treatment period A detailed summary of adverse events is located in the Reported Adverse Event Module. | From initiation of study drug to end of study (up to 8 months) | No |
Secondary | Number of Participants With = 1 Hematology Abnormality and = 1 Grade 3 or Higher Hematology Abnormality | Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) | No | |
Secondary | Number of Participants With = 1 Chemistry Laboratory Abnormality and = 1 Grade 3 or Higher Chemistry Laboratory Abnormality | Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) | No | |
Secondary | Number of Participants With = 1 Urinalysis Abnormality and = 1 Grade 3 or Higher Urinalysis Abnormality | Screening through End of Study Visit (Within 30 [±7] days following withdrawal of study treatment) | No | |
Secondary | Best Objective Tumor Response | Complete Response (CR): Complete disappearance of all measurable and non-measurable disease with no new lesions. Any pathological lymph node (target or non-target) must have a reduction in short axis to < 10 mm). All markers of disease must have normalized. Partial Response (PR): A decrease from baseline of = 30% of the diameter(s) of all target measurable lesions with no unequivocal progression of non-measurable lesions and no new lesions. Stable Disease (SD): Does not qualify for CR, PR, or progression. Disease Progression (PD): If at least one of following criteria is met: 1. Appearance of any new lesion or site of disease. 2. A 20% increase in the sum of the diameter(s) of target measurable lesions over either the smallest sum observed or over baseline if no decrease during therapy has occurred. The sum must also demonstrate an absolute increase of at least 5 mm. 3. Unequivocal progression of non-target lesions alone. | Baseline to measured progressive disease (up to approximately 12 months) | No |
Secondary | Overall Response Rate (ORR) and Disease Control Rate | Participants were defined as having an "overall response" if their best response is either confirmed CR, confirmed PR, unconfirmed CR or unconfirmed PR. ORR was defined as the percent of participants who had an overall response. Participants were defined as having "disease control" if their best response is confirmed CR, confirmed PR, unconfirmed CR, unconfirmed PR or SD. The disease control rate (DCR) was defined as the percent of participants with disease control. (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.) | Baseline to measured progressive disease (up to approximately 12 months) | No |
Secondary | Duration of Overall Response Rate | Overall response was defined has having a response of Complete Response (CR) or Partial Response (PR). (See "Best Objective Tumor Response" Outcome Measure above for response category definitions.) Duration of Response is defined as the duration from the first overall response to the first Stable Disease (SD) or Disease Progression (PD), whichever happens first. If no SD or PD, subject is censored at the last tumor assessment (prior to other anti-cancer therapy if applicable). | Baseline to measured progressive disease (up to approximately 12 months) | No |
Secondary | Progression-free Survival (PFS) | PFS was defined as the time from randomization to the date of disease progression or death, whichever occurred first, before or after treatment discontinuation. For participants still on study and those who remained alive and had not progressed after treatment discontinuation, PFS was censored on the date of the last tumor assessment. | Baseline to measured progressive disease (up to approximately 12 months) | No |
Secondary | Change From Baseline in Serum Hsp27 levels by End of Treatment | End of Treatment is last non-hemolyzed observation up to last dose + 30 days. Includes unscheduled and additional treatment visits. Hemolyzed samples were excluded. | Baseline, End of Treatment (up to approximately 12 months) | No |
Secondary | Change From Baseline in Serum Clusterin Levels by End of Treatment | End of Treatment is last observation up to last dose + 30 days. Includes unscheduled and additional treatment visits. | Baseline, End of Treatment (up to approximately 12 months) | No |
Secondary | Change From Baseline in Circulating Tumor Cell (CTC) Count by End of Treatment | End of Treatment is last observation up to last dose + 30 days. Includes unscheduled and additional treatment visits. | Baseline, End of Treatment (up to approximately 12 months) | No |
Secondary | Serum OGX-427 Cmax and Trough Levels | only C1 to C6, Ctrough and Cmax - as well report EOT Ctrough | Cycle 1 Day 1 through Cycle 6 Day 1, End of Treatment (up to approximately 12 months) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00151034 -
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Completed |
NCT04052113 -
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
|
||
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05025930 -
Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000).
|
N/A | |
Not yet recruiting |
NCT05135520 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen
|
N/A | |
Withdrawn |
NCT04630483 -
Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
|
||
Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04644432 -
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05308771 -
To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery
|
N/A | |
Terminated |
NCT00226954 -
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT05113134 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen
|
N/A | |
Completed |
NCT04213157 -
Laparoscopic Partial Nephrectomy for cT1 Tumors
|
||
Completed |
NCT02780687 -
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04922047 -
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 | |
Recruiting |
NCT05935748 -
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
|
Phase 2 |